NKNak-Jung Kwon

Nak-Jung Kwon

*This is an algorithmically generated author record based on publicly available information.

Nak-Jung Kwon has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development and validation of a multimodal data collection system for adolescent mental health management

    by Siyeon Ko, Kyoungsu Oh, Uhyeong Won, Jung-A Oh, Nak-Jung Kwon, Hyun-Sook Park, Young-A Ji, Sungjin Kim, Yonghwan Moon, Nayoung Park, et al.

    Objective: Adolescence is a critical developmental stage during which mental health vulnerabilities often emerge. Traditional self-report methods are insufficient to capture the complexity of emotional and physiological responses, underscoring the need for data-driven, personalized mental health strategies. This study aimed to develop and validate a structured multimodal data collection system for adolescents to support the future advancement of precision mental health care. Methods: This study was conducted as the baseline phase of a longitudinal panel study designed to construct and validate a structured multimodal dataset for adolescent mental health research. A total of 74 adolescents aged 11–15 years from schools and community facilities in Korea was selected through convenience sampling. Multimodal data were collected by integrating six data types: self-reported surveys, electroencephalography (EEG), heart rate variability (HRV), genotyping, microbiome data, and video-based psychological counseling. Data collection was standardized through a three-phase protocol (pre-, on-site, and post-assessment), and participant privacy was protected via pseudonymization based on international standards. Variables were systematically labeled and structured to enable cross-modality analysis. Statistical analyses, including correlation and descriptive statistics, were performed to examine preliminary relationships across modalities. Results: The study successfully constructed a comprehensive dataset encompassing biological and psychosocial indicators from 74 adolescents. Preliminary analysis revealed statistically significant associations between survey-based BMI and both genomic data (ρ = 0.30, p < 0.01) and microbiome-based obesity indicators (ρ = 0.27, p < 0.05), whereas other psychological constructs (e.g., stress, resilience) showed non-significant cross-modal correlations. Conclusions: This study presents a replicable framework for collecting rich, multimodal data from adolescents in real-world settings. By enabling integrative analysis of biological and psychosocial variables, the dataset lays the groundwork for personalized mental health prediction and intervention strategies. Future research should expand longitudinally and optimize context alignment to improve predictive precision and clinical utility.

  • Open Access

    Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy

    by Seung-Been Lee, Ji-Won Kim, Hong-Geun Kim, Sung-Hyun Hwang, Kui-Jin Kim, Ju Hyun Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Koung Jin Suh, et al.

    Purpose This study aimed to compare tumor tissue DNA (ttDNA) and circulating tumor DNA (ctDNA) to explore the clinical applicability of ctDNA and to better understand clonal evolution in patients with metastatic colorectal cancer undergoing palliative first-line systemic therapy.Materials and Methods We performed targeted sequencing analysis of 88 cancer-associated genes using germline DNA, ctDNA at baseline (baseline-ctDNA), and ctDNA at progressive disease (PD-ctDNA). The results were compared with ttDNA data.Results Among 208 consecutively enrolled patients, we selected 84 (41 males; median age, 59 years; range, 35 to 90 years) with all four sample types available. A total of 202 driver mutations were found in 34 genes. ttDNA exhibited the highest mutation frequency (n=232), followed by baseline-ctDNA (n=155) and PD-ctDNA (n=117). Sequencing ctDNA alongside ttDNA revealed additional mutations in 40 patients (47.6%). PD-ctDNA detected 13 novel mutations in 10 patients (11.9%) compared to ttDNA and baseline-ctDNA. Notably, seven mutations in five patients (6.0%) were missense or nonsense mutations in APC, TP53, SMAD4, and CDH1 genes. In baseline-ctDNA, higher maximal variant allele frequency (VAF) values (p=0.010) and higher VAF values of APC (p=0.012), TP53 (p=0.012), and KRAS (p=0.005) mutations were significantly associated with worse overall survival.Conclusion While ttDNA remains more sensitive than ctDNA, our ctDNA platform demonstrated validity and potential value when ttDNA was unavailable. Post-treatment analysis of PD-ctDNA unveiled new pathogenic mutations, signifying cancer’s clonal evolution. Additionally, baseline-ctDNA’s VAF values were prognostic after treatment.


  • T cell receptor clonotype in tumor microenvironment contributes to intratumoral signaling network in patients with colorectal cancer

    by In Hye Song, Seung-Been Lee, Byung-Kwan Jeong, Jungwook Park, Honggeun Kim, GunHee Lee, Su Min Cha, Heejae Lee, Gyungyub Gong, Nak-Jung Kwon, et al.

    Single-cell RNA sequencing (scRNA-seq) has contributed to understanding cellular heterogeneity and immune profiling in cancer. The aim of the study was to investigate gene expression and immune profiling in colorectal cancer (CRC) using scRNA-seq. We analyzed single-cell gene expression and T cell receptor (TCR) sequences in 30 pairs of CRC and matched normal tissue. Intratumoral lymphocytes were measured with digital image analysis. CRC had more T cells, epithelial cells, and myeloid cells than normal colorectal tissue. CRCs with microsatellite instability had more abundant T cells than those without microsatellite instability. Immune cell compositions of CRC and normal colorectal tissue were inversely correlated. CD4 + or CD8 + proliferating T cells, CD4 + effector memory T cells, CD8 + naïve T cells, and regulatory T cells of CRC showed higher TCR clonal expansion. Tumor epithelial cells interacted with immune cells more strongly than normal. T cells, myeloid cells, and fibroblasts from CRCs of expanded T cell clonotypes showed increased expression of genes related to TNF and NFKB signaling and T cell activation. CRCs of expanded T cell clonotypes also showed stronger cellular interactions among immune cells, fibroblasts, and endothelial cells. Pro-inflammatory CXCL and TNF signaling were activated in CRCs of expanded T cell clonotype. In conclusion, scRNA-seq analysis revealed different immune cell compositions, differential gene expression, and diverse TCR clonotype dynamics in CRC. TCR clonality expansion is associated with immune activation through T cell signaling and chemokine signaling. Patients with CRCs of expanded clonotype can be promising candidates for immunotherapy.


  • Open Access

    MUC16 as a serum-based prognostic indicator of prometastatic gastric cancer

    by Jieun Lee, Sang Wook Lee, So Hyun Kang, Donghyeok Seol, Mira Yoo, Duyeong Hwang, Eunju Lee, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, et al.

    Metastatic gastric cancer (GC) presents significant clinical challenges due to its poor prognosis and limited treatment options. To address this, we conducted a targeted protein biomarker discovery study to identify markers predictive of metastasis in advanced GC (AGC). Serum samples from 176 AGC patients (T stage 3 or higher) were analyzed using the Olink Proteomics Target panels. Patients were retrospectively categorized into nonmetastatic, metastatic, and recurrence groups, and differential protein expression was assessed. Machine learning and gene set enrichment analysis (GSEA) methods were applied to discover biomarkers and predict prognosis. Four proteins (MUC16, CAIX, 5’-NT, and CD8A) were significantly elevated in metastatic GC patients compared to the control group. Additionally, GSEA indicated that the response to interleukin-4 and hypoxia-related pathways were enriched in metastatic patients. Random forest classification and decision-tree modeling showed that MUC16 could be a predictive marker for metastasis in GC patients. Additionally, ELISA validation confirmed elevated MUC16 levels in metastatic patients. Notably, high MUC16 levels were independently associated with metastatic progression in T3 or higher GC. These findings suggest the potential of MUC16 as a clinically relevant biomarker for identifying GC patients at high risk of metastasis.


  • Open Access

    Multiplex analysis for the identification of plasma protein biomarkers for predicting lung cancer immunotherapy response

    by Moonki Hong, Sang Wook Lee, Byoung Chul Cho, Min Hee Hong, Sun Min Lim, Nak-Jung Kwon

    Background: Programmed death-ligand (PD-L1) expression serves as a predictive biomarker for immune checkpoint inhibitor (ICI) sensitivity in non-small cell lung cancer (NSCLC). Nevertheless, the development of biomarkers that reliably predict ICI response remains an ongoing endeavor due to imperfections in existing methodologies. Objectives: ICIs have led to a new paradigm in the treatment of NSCLC. The current companion PD-L1 diagnostics are insufficient in predicting ICI response. Therefore, we sought whether the Olink platform could be applied to predict response to ICIs in NSCLC. Design: We collected blood samples from patients with NSCLC before ICI treatment and retrospectively analyzed proteomes based on their response to ICI. Methods: Overall, 76 NSCLC patients’ samples were analyzed. Proteomic plasma analysis was performed using the Olink platform. Intraplate reproducibility, validation, and statistical analyses using elastic net regression and generalized linear models with clinical parameters were evaluated. Results: Intraplate coefficient of variation (CV) assays ranged from 3% to 6%, and the interplate CV was 14%. In addition, the Pearson correlation coefficient of the Olink Normalized Protein eXpression data was validated. No statistical differences were observed in the analyses of progressive disease and response to ICIs. Furthermore, no single proteome showed prognostic value in terms of progression-free survival. Conclusion: In this study, the proximity extension assay-based approach of the Olink panel could not predict the patient’s response to ICIs. Our proteomic analysis failed to achieve predictive value in both response or progression to ICIs and progression-free survival (PFS).


  • Open Access

    The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA

    by Won Jin Chang, Jae Sook Sung, Sung Yong Lee, Eun Joo Kang, Nak-Jung Kwon, Hae Mi Kim, Sang Won Shin, Jung Yoon Choi, Yoon Ji Choi, Ju Won Kim, et al.

    Mutations in the EGFR gene downstream signaling pathways may cause receptor-independent pathway activation, making tumors unresponsive to EGFR inhibitors. However, the clinical significance of RAS, PIK3CA or PTEN mutations in NSCLC is unclear. In this study, patients who were initially diagnosed with NSCLC or experienced recurrence after surgical resection were enrolled, and blood samples was collected. Ultra-deep sequencing analysis of cfDNA using Ion AmpliSeq Cancer Hotspot Panel v2 with Proton platforms was conducted. RAS/PIK3CA/PTEN mutations were frequently detected in cfDNA in stage IV NSCLC (58.1%), and a high proportion of the patients (47.8%) with mutations had bone metastases at diagnosis. The frequency of RAS/PIK3CA/PTEN mutations in patients with activating EGFR mutation was 61.7%. The median PFS for EGFR-TKIs was 15.1 months in patients without RAS/PIK3CA/PTEN mutations, and 19.9 months in patients with mutations (p = 0.549). For patients with activating EGFR mutations, the overall survival was longer in patients without RAS/PIK3CA/PTEN mutations (53.8 months vs. 27.4 months). For the multivariate analysis, RAS/PIK3CA/PTEN mutations were independent predictors of poor prognosis in patients with activating EGFR mutations. In conclusion, RAS, PIK3CA and PTEN mutations do not hamper EGFR-TKI treatment outcome; however, they predict a poor OS when activating EGFR mutations coexist.


  • Open Access

    Virus Isolation from the First Patient with SARS-CoV-2 in Korea

    by Wan Beom Park, Nak-Jung Kwon, Su-Jin Choi, Chang Kyung Kang, Pyoeng Gyun Choe, Jin Yong Kim, Jiyoung Yun, Gir-Won Lee, Moon-Woo Seong, Nam Joong Kim, et al.

    Park WB, et al. J Korean Med Sci. 2019 Dec;35(7):e84. https://doi.org/10.3346/jkms.2020.35.e84


  • Open Access

    Analysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers

    by Ha Youn Lee, Se-Hoon Lee, Jae-Kyung Won, Dong Soo Lee, Nak-Jung Kwon, Sun Mi Choi, Jinwoo Lee, Chang-Hoon Lee, Sang-Min Lee, Jae-Joon Yim, et al.

    Lee HY, et al. J Korean Med Sci. 2017 Mar;32(3):415-420. https://doi.org/10.3346/jkms.2017.32.3.415


  • Open Access

    Isolation of Middle East Respiratory Syndrome Coronavirus from a Patient of the 2015 Korean Outbreak

    by Wan Beom Park, Nak-Jung Kwon, Pyoeng Gyun Choe, Su-Jin Choi, Hong Sang Oh, Sang Min Lee, Hyonyong Chong, Jong-Il Kim, Kyoung-Ho Song, Ji Hwan Bang, et al.

    Park WB, et al. J Korean Med Sci. 2016 Feb;31(2):315-320. http://dx.doi.org/10.3346/jkms.2016.31.2.315